Ftse Mib
34.720,35
0,90%
DAX
19.473,63
1,32%
S&P 500
5.740,48
-0,09%
NASDAQ
18.120,21
-0,39%
Bitcoin
65.713,91
0,81%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vanda Pharmaceuticals Inc (VNDA) Vanda Pharmaceuticals Inc (VNDA) Notizie

VNDA

Vanda Pharmaceuticals (VNDA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VNDA
DataOraFonteTitoloSimboloCompagnia
19/09/202414:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
19/09/202413:00PR Newswire (US)FDA Declines to Approve Vanda's Marketing Application for Tradipitant in GastroparesisNASDAQ:VNDAVanda Pharmaceuticals Inc
11/09/202423:00PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
04/09/202423:13PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
29/08/202422:30PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
08/08/202413:47Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
01/08/202413:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
31/07/202422:01PR Newswire (US)Vanda Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
29/07/202423:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
29/07/202423:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
26/07/202415:19PR Newswire (US)Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
01/07/202414:01PR Newswire (US)Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and ApotexNASDAQ:VNDAVanda Pharmaceuticals Inc
20/06/202402:48PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
13/06/202416:02PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
06/06/202415:24PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.NASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202423:20PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202422:48PR Newswire (US)Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®NASDAQ:VNDAVanda Pharmaceuticals Inc
29/05/202420:17PR Newswire (US)Vanda Pharmaceuticals Announces Presentations at SLEEP 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202422:46PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202422:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202422:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VNDAVanda Pharmaceuticals Inc
15/05/202414:45PR Newswire (US)Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessNASDAQ:VNDAVanda Pharmaceuticals Inc
13/05/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202422:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202422:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202414:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
23/04/202401:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202416:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202415:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202416:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VNDA

La tua Cronologia

BIT
MONC
Moncler
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
CPR
Davide Campari
BIT
BC
Brunello Cucinelli
BIT
TEN
Tenaris
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network